Baylor College of Medicine: Targeting Transforming Growth Factor-Beta for Treatment of Osteogenesis Imperfecta
February 16, 2022
February 16, 2022
HOUSTON, Texas, Feb. 16 (TNSJou) -- The Baylor College of Medicine issued the following news:
A new study led by Baylor College of Medicine identifies an underlying mechanism of pathogenesis for osteogenesis imperfecta (OI) in human bone. The report, published in the Journal of Clinical Investigation, also shows the results of a Phase 1 clinical trial testing the safety and effectiveness of an antibody treatment targeting that pathway.
Osteogenesis imperfecta is the mos . . .
A new study led by Baylor College of Medicine identifies an underlying mechanism of pathogenesis for osteogenesis imperfecta (OI) in human bone. The report, published in the Journal of Clinical Investigation, also shows the results of a Phase 1 clinical trial testing the safety and effectiveness of an antibody treatment targeting that pathway.
Osteogenesis imperfecta is the mos . . .